Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Masato Shizuku; Nobuhiko Kurata; Kanta Jobara; Yasuhiro Fujimoto; Yasuhiro Ogura

doi:10.12659/AOT.941456

15 December 2023: Original Paper

Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Masato Shizuku ^123ABCDEF , Nobuhiko Kurata ^1B , Kanta Jobara ^1B , Yasuhiro Fujimoto ^1B , Yasuhiro Ogura ^1ABCDFG*

DOI: 10.12659/AOT.941456

Ann Transplant 2023; 28:e941456

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 Desensitization protocol for liver transplant recipients with pDSA. FK506 – tacrolimus; HLA – human leukocyte antigen; MP – methylprednisolone; pDSA – preformed donor-specific antibody. * Splenectomy was performed when portal hypertension was present.

Back to the Article

Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Your Privacy